Terms ending in 2033
Every in-force patent on Rigel Pharmaceuticals, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,927,564 | Synthesis of Polycyclic Alkaloids In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,353,112 | Synthesis of Polycyclic Alkaloids In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,005,909 | Whole Blood Assay for Measuring Ampk Activation In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,682,976 | Protein Kinase C Inhibitors and Uses Thereof In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,034,881 | Treatment for Vitiligo In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,145,433 | GDF-8 Inhibitors In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,981,944 | GDF-8 Inhibitors In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,321,763 | Protein Kinase C Inhibitors and Uses Thereof In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | |
| US 9,062,068 | Protein Kinase C Inhibitors and Uses Thereof In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.